Q-omics provides the consensus-scored DES profile across patient tissues and cancer cell-line models. DES expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DES is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, DES protein abundance shows 25,938 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where DES shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DES — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DES survival associations across molecular data types. DES RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DES RNA expression–survival associations across cancer types. High DES expression shows unfavorable associations in KIRP, HNSC, BLCA, LGG and LUSC, but favorable associations in CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DES RNA expression.
This table summarizes DES tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DES. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DES shows lower tumor expression in BLCA, THCA, KIRC, KICH, LUAD and UCEC. The BLCA box plot shows higher DES RNA expression in normal versus tumor tissue (log2 FC = −9.591, t-test p < 0.001).
This table shows molecular features associated with DES in patient tissues and cancer cell lines. In patient samples, DES shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DES RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
